ArriVent BioPharma

AVBP

시가총액 US$8.21억

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Arrivent securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.

ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.

NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.

LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.

AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway.

AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- A 56.7% premarket plunge hit AVBP shareholders on October 6, 2026, after ArriVent BioPharma (NASDAQ: AVBP) announced that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint.

ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.

ArriVent BioPharma said on Tuesday its oral therapy to treat ‌patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial, sending ​shares down 63% in premarket trading.

NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR).

The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration across EGFR exon 20 insertion and PACC populations. Pipeline optionality is expanding, with ARR-217 entering Phase 1 and ARR-002 approaching first-patient dosing.